Sarepta Therapeutics (SRPT) Cash & Current Investments (2010 - 2026)

Sarepta Therapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $405.6 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 22.42% year-over-year to $405.6 million; the TTM figure through Mar 2026 stood at $405.6 million (down 22.42% YoY), while the FY2025 annual figure was $939.6 million, down 14.26% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $405.6 million, down from $939.6 million in the prior quarter.
• The five-year high for Cash & Current Investments was $2.1 billion in Q3 2022, with the low at $242.5 million in Q3 2024.
• The 5-year median for Cash & Current Investments is $1.5 billion (2024), against an average of $1.3 billion.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments plunged 86.01% in 2024, then surged 164.96% in 2025.
• Sarepta Therapeutics' Cash & Current Investments stood at $2.0 billion in 2022, then slipped by 15.74% to $1.7 billion in 2023, then tumbled by 34.62% to $1.1 billion in 2024, then retreated by 14.26% to $939.6 million in 2025, then slumped by 56.84% to $405.6 million in 2026.
• Business Quant data shows SRPT's Cash & Current Investments at $405.6 million in Q1 2026, $939.6 million in Q4 2025, and $642.5 million in Q3 2025.